Anthracycline-free platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: efficacy, safety, and clinicopathological predictors of response
DOI: 10.32364/2587-6821-2026-10-6-2
Anthracycline-free platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: efficacy, safety, and clinicopathological predictors of response
E.I. Ratova1, L.V. Bolotina1, A.D. Kaprin1,2
1P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiology Centre, Moscow, Russian Federation
2RUDN University, Moscow, Russian Federation
Background: triple-negative breast cancer (TNBC) is associated with aggressive tumor biology and limited systemic treatment options. Incorporation of platinum agents into neoadjuvant chemotherapy (NACT) can increase pathological complete response (pCR) rates, but platinum-based regimens containing anthracyclines are often accompanied by substantial toxicity. Anthracycline omission has therefore been proposed as a de-escalation strategy that may preserve antitumor efficacy while improving tolerability. However, evidence regarding anthracycline-free platinum-based NACT and predictors of response remains limited.
Aim: to assess the efficacy and safety of an anthracycline-free platinum-based NACT regimen and to identify clinicopathological factors associated with pCR in patients with operable TNBC.
Materials and Methods: this prospective single-center study enrolled 50 patients with stage I–IIIA TNBC. All patients received six cycles of carboplatin AUC 5–6 plus paclitaxel 80 mg/m2 administered weekly. The primary endpoint was pCR, defined as ypT0/is ypN0. Secondary endpoints included safety, event-free survival (EFS), and analysis of predictors of response. Statistical methods included univariate and multivariate logistic regression, receiver operating characteristic (ROC) analysis, and comparative model assessment using the Akaike information criterion.
Results: pCR was achieved in 60.0% of patients. After a median follow-up of 15.3 months, the 1-year EFS rate was 100%. The treatment regimen showed a favorable safety profile, with no reported cases of febrile neutropenia, grade 3–4 non-hematologic toxicity, or cardiotoxicity. BRCA1/2 mutations and higher Ki-67 levels were associated with a greater likelihood of pCR; Ki-67 remained statistically significant in multivariate analysis.
Conclusion: anthracycline-free neoadjuvant chemotherapy with carboplatin plus paclitaxel demonstrated substantial efficacy and favorable tolerability in patients with operable TNBC. BRCA1/2 mutation status and high Ki-67 levels were associated with pCR and may represent potential predictors of response. These results warrant further evaluation of anthracycline-free platinum-based regimens in randomized clinical trials.
Keywords: triple-negative breast cancer, neoadjuvant chemotherapy, pathological complete response, platinum-containing therapy, anthracycline-free regimen, BRCA1/2 mutations, Ki-67, TILs.
For citation: Ratova E.I., Bolotina L.V., Kaprin A.D. Anthracycline-free platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: efficacy, safety, and clinicopathological predictors of response. Russian Medical Inquiry. 2026;10(7):465–473 (in Russ.). DOI: 10.32364/2587-6821-2026-10-7-2
About the authors:
Evgenia I. Ratova — oncologist, postgraduate student of the Chemotherapy Department, Division of Anticancer Drug Therapy, P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiology Centre; 3, 2nd Botkinsky Passage, Moscow, 125284, Russian Federation; ORCID iD 0000-0001-5505-037
Larisa V. Bolotina — Dr. Sc. (Med.), Professor of the Russian Academy of Sciences, Head of the Chemotherapy Department, Division of Anticancer Drug Therapy, P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiology Centre; 3, 2nd Botkinsky Passage, Moscow, 125284, Russian Federation; ORCID iD 0000-0003-4879-2687
Andrey D. Kaprin — Dr. Sc. (Med.), Professor, Academician of the Russian Academy of Sciences, Academician of the Russian Academy of Education; General Director of the National Medical Research Radiology Centre; Director, P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiology Centre; 3, 2nd Botkinsky Passage, Moscow, 125284, Russian Federation; Head of the Department of Oncology and Radiology named after Academician V.P. Kharchenko, Medical Institute, RUDN University; 6, Miklukho-Maklaya str., Moscow, 117198, Russian Federation; ORCID iD 0000-0001-8784-8415.
Contact information: Evgenia I. Ratova, e-mail: ratovaevgenia@yandex.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 01.04.2026.
Revised 24.04.2026.
Accepted 21.05.2026.
2. Liedtke C., Mazouni C., Hess K. et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol. 2023;41(10):1809–1815. DOI: 10.1200/JCO.22.02572
3. von Minckwitz G., Schneeweiss A., Loibl S. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–756. DOI: 10.1016/S1470-2045(14)70160-3
4. Sikov W., Berry D., Perou C. et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13–21. DOI: 10.1200/JCO.2014.57.0572
5. Geyer C.E., Sikov W.M., Huober J. et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022;33(4):384–394. DOI: 10.1016/j.annonc.2022.01.009
6. Sohn J., Kim G.M., Jung K.H. et al. A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15–1 PEARLY trial. J Clin Oncol. 42, 2024;42(suppl 17):abstr. LBA502. DOI: 10.1200/JCO.2024.42.17_suppl.LBA502
7. Cortazar P., Zhang L., Untch M. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. DOI: 10.1016/S0140-6736(13)62422-8. Erratum in: Lancet. 2019;393(10175):986. DOI: 10.1016/S0140-6736(18)32772-7
8. Poggio F., Bruzzone M., Ceppi M. et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497–1508. DOI: 10.1093/annonc/mdy127
9. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879. DOI: 10.1002/cncr.11407
10. Bostany G., Chen Y., Francisco L. et al. Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors. J Clin Oncol. 2025;43(1):32–45. DOI: 10.1200/JCO.23.01779
11. Sharma P., Kimler B.F., O'Dea A. et al. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP). Clin Cancer Res. 2021;27(4):975–982. DOI: 10.1158/1078-0432.CCR-20-3646
12. Zhang L., Wu Z.Y., Li J. et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial. Int J Cancer. 2022;150(4):654–662. DOI: 10.1002/ijc.33830
13. Gluz O., Nitz U., Kolberg-Liedtke C. et al. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clin Cancer Res. 2022;28(22):4995–5003. DOI: 10.1158/1078-0432.CCR-22-0482
14. Гордеева О.О., Колядина И.В., Жукова Л.Г. и др. Эффективность и безопасность неоадъювантной химиотерапии в режиме PlaTax у больных трижды негативным раком молочной железы II–III стадий. Опухоли женской репродуктивной системы. 2020;16(2):25–37. DOI: 10.17650/1994-4098-2020-16-2-25-37. Gordeeva O.O., Kolyadina I.V., Zhukova L.G. et al. Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer. Tumors of female reproductive system. 2020;16(2):25–37 (in Russ.). DOI: 10.17650/1994-4098-2020-16-2-25-37
15. Garrido-Castro A., Lin N., Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019;9(2):176–198. DOI: 10.1158/2159-8290.CD-18-1177
16. Salgado R., Denkert C., Demaria S. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–271. DOI: 10.1093/annonc/mdu450
17. Schmid P., Cortes J., Pusztai L. et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810–821. DOI: 10.1056/nejmoa1910549
18. Tutt A., Tovey H., Cheang. M.C. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24:628–637. DOI: 10.1038/s41591-018-0009-7
19. Silver D.P., Richardson A.L., Eklund A.C. et al. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. J Clin Oncol. 2010;28(7):1145–1153. DOI: 10.1200/JCO.2009.22.472
20. Byrski T., Huzarski T., Dent R. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115(2):359–363. DOI: 10.1007/s10549-008-0128-9
21. Turner N.C., Tutt A.N. Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? Breast Cancer Res. 2012;14(6):115. DOI: 10.1186/bcr3332
22. Toli M., Liu X., Massa D. et al. Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study. Lancet Reg Health Eur. 2025;58:101432. DOI: 10.1016/j.lanepe.2025.101432
23. Wang, R.X., Chen S., Jin X., Shao Z.M. Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Sci Rep. 2016;6(1):30091. DOI: 10.1038/srep30091
24. Denkert C., Minckwitz G., Darb-Esfahani S. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. DOI: 10.1016/S1470-2045(17)30904-X
25. O'Shaughnessy J., Cortes J., Dent R. et al. Exploratory Biomarker Analysis of the Phase 3 KEYNOTE 522 Study (LB1 07). San Antonio Breast Cancer Symposium (SABCS) 2024; Abstract LB1 07. DOI: 10.1158/1557-3265.SABCS24-LB1-07
26. Gupta S., Nair N., Hawaldar R.W. et al. Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2026;44(1):9–19. DOI: 10.1200/JCO-25-01023
This work is licensed under a Creative Commons «Attribution» 4.0 License.
